Reason for request
The actual benefit of ORENCIA is substantial.
Clinical Added Value
|no clinical added value||
In the indication: "treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) or a TNF-alpha inhibitor, ORENCIA does not provide an improvement in actual benefit (IAB V).